Related Experiment Video

Updated: Oct 5, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

[QTc interval in newborns with gastroesophageal reflux treated with cisapride and ranitidine]

G Lista1, L Maestri, M Meroni

  • 1U.O di Terapia Intensiva Neonatale, Ospedale Buzzi, ICP Milano, Italia.

Acta Bio-Medica De L'Ateneo Parmense : Organo Della Societa Di Medicina E Scienze Naturali Di Parma
|June 27, 2001
PubMed

Insights

Low-dose cisapride therapy is safe for infants with gastroesophageal reflux (GER). This study found no significant adverse cardiac effects in pediatric patients receiving this common treatment.

Area of Science:

  • Pediatric Gastroenterology
  • Infant Cardiology
  • Clinical Pharmacology

Context:

  • Gastroesophageal reflux (GER) is prevalent in infants, particularly premature infants.
  • GER can manifest with gastrointestinal and cardiorespiratory symptoms.
  • Cisapride, a prokinetic agent, is used to manage GER by preventing esophageal sphincter relaxation.

Purpose:

  • To evaluate the safety and effects of low-dose cisapride therapy on the QTc interval in infants with GER.
  • To assess the cardiac safety profile of cisapride in a pediatric population.

Summary:

  • The study investigated cisapride therapy at a dosage of 0.8 mg/Kg/day in 50 infants diagnosed with GER.
  • Electrocardiograms (EKGs) were monitored to assess the QTc interval (QT interval corrected for heart rate).
  • Results indicated that low-dose cisapride therapy is relatively safe in pediatric patients with GER.

Impact:

  • Provides evidence for the safety of low-dose cisapride in managing infant GER.
  • Informs clinical practice regarding the use of cisapride in pediatric populations.
  • Contributes to understanding the cardiac safety of prokinetic agents in infants.

More Related Videos

Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice07:41

Video Imaging and Spatiotemporal Maps to Analyze Gastrointestinal Motility in Mice

Published on: February 3, 2016

Electrocardiogram Recordings in Anesthetized Mice using Lead II04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Gastroesophageal Reflux Disease01:25

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is the backward flow of stomach contents (acid, pepsin, or bile) into the esophagus, causing mucosal inflammation known as esophagitis. It results from failure of antireflux mechanisms, mainly the lower esophageal sphincter (LES), influenced by mechanical and physiological factors.Etiology and Risk FactorsGERD develops when LES function is weakened or when intra-abdominal pressure increases. Risk factors include aging, obesity, and sliding hiatal hernia,...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Pyloric Obstruction01:11

Pyloric Obstruction

Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...